Search for: "AMGEN INC."
Results 241 - 260
of 704
Sorted by Relevance
|
Sort by Date
13 Jan 2014, 2:33 pm
By:David Gabor On December 30, 2013, the Federal Court of Appeals, in Allergan, Inc. v. [read post]
1 Apr 2008, 2:16 am
Teva Pharmaceuticals USA, Inc. [read post]
1 Jul 2022, 10:02 am
The current most-likely big case is Amgen Inc., et al. v. [read post]
5 Feb 2007, 6:47 pm
A Co-Owner Has a Right to Limit Another Co-Owner's Ability to Sue Infringers by Refusing to Join Voluntarily in a Suit. [read post]
16 Sep 2009, 7:45 am
The Federal Circuit, in Amgen Inc. v. [read post]
16 Jun 2012, 3:10 pm
(Amgen Inc. v. [read post]
26 Apr 2017, 4:17 am
The first is Amgen Inc. v. [read post]
6 Oct 2017, 2:34 pm
CAFC holds that later-developed antibody species may be evidence that a claimed antibody genus is invalid for lack of written description, and casts doubt on the “antibody exception” Amgen Inc. v. [read post]
6 Oct 2017, 2:34 pm
CAFC holds that later-developed antibody species may be evidence that a claimed antibody genus is invalid for lack of written description, and casts doubt on the “antibody exception” Amgen Inc. v. [read post]
18 Jul 2013, 12:00 pm
The SECobtained an emergency court order to freeze the assets of traders using foreign accounts to reap approximately $4.6 million in potentially illegal profits by trading in advance of the Sunday, June 30, 2013 announcement that Onyx Pharmaceuticals, Inc. had received, but rejected an acquisition offer from Amgen, Inc.The SEC alleges that unknown traders took risky bets that Onyx's stock price would increase by purchasing call options on June 26, 27 and 28, the three trading days… [read post]
9 Aug 2016, 7:50 am
" Amgen Inc. et al v. [read post]
23 Sep 2010, 12:19 am
Amgen, Inc., Judge William G. [read post]
21 Apr 2023, 7:07 am
Amgen Inc., v. [read post]
11 Jul 2008, 4:08 am
Noonan -- Insmed Inc. announced today that a just-completed clinical trial showed that its INS-19 product, a recombinant human granulocyte colony stimulating factor (G-CSF) was "bioequivalent" to Amgen's FDA-approved Neupogen ®, a product used for treating neutropenia, a blood deficiency disorder associated with, inter alia, chemotherapeutic drug treatment. [read post]
3 Sep 2019, 8:24 am
by Dennis Crouch Amgen v. [read post]
16 Aug 2017, 8:21 am
Amgen, Inc., 137 S. [read post]
13 Feb 2009, 9:43 pm
Insmed's pipeline of follow-on biologics includes biosimilar versions of Amgen's Neupogen and Neulasta. [read post]
6 Nov 2021, 9:15 pm
In the second installment of a three part series, Emily Johnson of Amgen, Inc., Jay Tatachar of Ericsson, Vaishali Udupa of Hewlett Packard Enterprise, Todd Walters of Buchanan Ingersoll & Rooney PC, and Jenifer Ward General Electric Co. will discuss the pros and cons of the various options for challenging the validity of patent claims, giving perspectives from both challenger and patent owner, and highlight... [read post]
29 Apr 2018, 8:48 pm
Emily Johnson of Amgen, Inc. will moderate a panel consisting of Allyson Ho of Morgan Lewis & Bockius LLP, Christopher Suarez of Williams & Connolly LLP, Gregory Castanias of Jones Day, and Russell Cass of Clark Hill PLC. [read post]
26 Oct 2018, 6:41 pm
Herbert Hart of McAndrews of Held & Malloy, Ltd. will moderate a panel consisting of Emily Johnson of Amgen Inc.; Barbara McCurdy of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; and the Hon. [read post]
